New strategy aims to keep lymphoma at bay after powerful CAR-T treatment
NCT ID NCT07198373
Summary
This study is looking at whether taking the drug zanubrutinib after receiving CAR-T cell therapy helps keep B-cell lymphoma from coming back. It will involve about 40 adults who have already had or are scheduled to get CAR-T treatment. The main goal is to see if this maintenance approach helps patients live longer without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.